Uterine Perforation with IUD Insertion
Uterine perforation occurs in approximately 0.87 to 2.1 per 1,000 IUD insertions overall, making it a rare but recognized complication. 1, 2, 3
Overall Incidence Rates
The absolute risk of uterine perforation varies by study methodology and follow-up duration:
- 0.87 per 1,000 insertions in a large U.S. cohort study with extended follow-up 1
- 2.1 per 1,000 insertions (95% CI: 1.6-2.8) for levonorgestrel-releasing IUDs in European data with 5-year follow-up 3
- 1.6 per 1,000 insertions (95% CI: 0.9-2.5) for copper IUDs in the same European cohort 3
- 0.6 to 16 per 1,000 insertions across various studies, with the wide range reflecting differences in detection methods and follow-up periods 4
The 5-year cumulative incidence is 0.61% (95% CI: 0.56-0.66%), which is approximately three times higher than the 1-year rate of 0.21%, indicating that approximately one-third of perforations are detected more than 12 months after insertion 3, 5
Risk Factors That Substantially Increase Perforation Risk
Postpartum Timing (Most Critical Factor)
IUD insertion between 4 days and 6 weeks postpartum carries the highest perforation risk, with an adjusted hazard ratio of 6.71 (95% CI: 4.80-9.38) compared to non-postpartum insertion 2, 5
Specific postpartum timing risks:
- 0-3 days postpartum: aHR 2.73 (95% CI: 1.33-5.63) 2
- 4 days to ≤6 weeks postpartum: aHR 6.71 (95% CI: 4.80-9.38) - highest risk period 2
- >6 weeks to ≤36 weeks postpartum: aHR 2.40 (95% CI: 1.70-3.39) 2
- Insertion at 4-8 weeks postpartum: 0.78% perforation rate versus 0.46% at 9-36 weeks (adjusted OR 1.92,95% CI: 1.28-2.89) 6
The elevated perforation risk persists until approximately 22-23 weeks postpartum, after which rates approach baseline 6
Breastfeeding Status
Breastfeeding at the time of IUD insertion increases perforation risk by 37% (aHR 1.37,95% CI: 1.12-1.66) among postpartum individuals, and by nearly 5-fold (RR 4.9,95% CI: 3.0-7.8) in perforations detected after 12 months 2, 3
Other Risk Factors
- History of abortion: Each additional abortion increases risk (OR 2.1,95% CI: 1.2-3.6) 7
- Lower parity: Higher parity is protective (OR 0.04,95% CI: 0.01-0.1) 7
- IUD type: Levonorgestrel-releasing IUDs have a borderline higher perforation risk compared to copper IUDs (adjusted OR 1.7,95% CI: 1.0-2.8) 3
Clinical Presentation and Detection
Approximately 58% of perforations are associated with identifiable risk factors, meaning 42% occur without obvious predisposing conditions 3
One-third of all perforations are not detected until more than 12 months after insertion, emphasizing the importance of long-term follow-up 3
Common presentations include:
- Lost IUD strings on examination 1
- Pelvic pain or cramping 1
- Abnormal bleeding 1
- Incidental finding on imaging 1
Clinical Significance and Morbidity
No perforations in large cohort studies resulted in serious injury to intra-abdominal or pelvic structures, and clinical sequelae are generally mild 3
The morbidity associated with detection and removal of perforated IUDs is low, with most cases managed successfully without major complications 3
Clinical Implications for Practice
Despite elevated relative risks in certain populations, the absolute perforation rate remains below 1% even in the highest-risk groups (4-8 weeks postpartum: 0.78%) 6
Women can safely be offered IUDs at any interval beyond 4 weeks postpartum with minimal concern for perforation, though counseling should acknowledge the slightly elevated risk in the 4-8 week window 6
The benefits of effective contraception and breastfeeding generally outweigh the small increased perforation risk, and IUD insertion timing should be based on individual desire for contraception and patient convenience 2
Key Counseling Points
- Overall perforation risk is less than 1 in 500 insertions in most populations 1, 2
- Risk is highest when inserting between 4 days and 6 weeks postpartum 2
- Breastfeeding slightly increases risk but should not preclude IUD use 2, 3
- Most perforations are detected late and have minimal clinical consequences 3
- Careful follow-up is warranted for individuals at higher risk 2